Trial Profile

A Phase 2 Study of Neoadjuvant Pembrolizumab-Based Combination Immunotherapy in the Treatment of Early Stage Non-Small Cell Lung Cancer

Status: Withdrawn prior to enrolment

Phase of Trial: Phase II

Latest Information Update: 17 May 2022

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Pembrolizumab (Primary) ; Cisplatin; Pemetrexed
Indications Non-small cell lung cancer
Focus Therapeutic Use

Most Recent Events

17 Feb 2022 Status changed from recruiting to withdrawn prior to enrolment.
04 Oct 2021 Planned End Date changed from 30 Apr 2022 to 31 Aug 2023.
04 Oct 2021 Planned primary completion date changed from 31 May 2021 to 31 Aug 2023.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com